A watershed in fighting cancer – but a miracle cure is a long way off | Charles Swanton

The latest advance in immunotherapy offers great hope, but there is much to learn before it can be translated into treatmentThese are exciting times to be a cancer researcher. The news this week that awoman ’s advanced breast cancer has apparently been eradicated by a therapy derived from her own immune system is a development many of us have waited a long time to hear. It ’spersonalised medicine, taken to the absolute limit, and a huge testimony to decades of hard work by a team of US researchers. And it ’s the sort of advance that genuinely deserves to be called a breakthrough.But those of us who treat people with advanced cancer have to balance the optimism of scientific progress with sober reality – this isn’t yet a cancer “treatment”, in the sense that is meaningful to our patients. The techniques used byDr Steve Rosenberg’s team at the US National Cancer Institute, and which many of us in the UK (including my own team) are also working on, are fearsomely complex, and currently far outside the routine clinical reality of an NHS cancer centre. That’s not because of funding, staff levels, or any of the other critic isms often levelled at our overstretched healthcare system – it’s because of the speed with which these insights have arrived. Naturally there will be a period of catch-up while they are tested more widely, and the infrastructure todeliver them routinely is put in place.Continue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Cancer research Breast cancer Medical research NHS Science Health Society UK news World news Source Type: news

Related Links:

Conclusions: WBRT remains the cornerstone of the management of brain metastases. The present study concludes that the survival of patients with brain metastases is significantly improved with female gender, good PS, primary breast cancer, time lag of>6 months between diagnosis of the primary tumor and development of brain metastases, solitary lesion, and controlled primary tumor.
Source: Indian Journal of Palliative Care - Category: Palliative Care Authors: Source Type: research
We presently forget 98% of everything we experience. That will go away in favor of perfect, controllable, configurable memory. Skills and knowledge will become commodities that can be purchased and installed. We will be able to feel exactly as we wish to feel at any given time. How we perceive the world will be mutable and subject to choice. How we think, the very fundamental basis of the mind, will also be mutable and subject to choice. We will merge with our machines, as Kurzweil puts it. The boundary between mind and computing device, between the individual and his or her tools, will blur. Over the course of the ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Publication date: Available online 19 June 2018Source: Pharmacology &TherapeuticsAuthor(s): Filipa Lynce, Ayesha N. Shajahan-Haq, Sandra M. SwainAbstractDysregulation of the cyclin dependent kinase pathway in luminal breast cancer creates a new therapeutic opportunity for estrogen receptor positive breast cancer. Initial pan-CDK inhibitors were associated with extensive toxicities but in recent years, the development of potent specific CDK inhibitors with favorable tolerability has driven renewed interests in this class of targeted therapies. Palbociclib, ribociclib and abemaciclib are specific CDK4/6 inhibitors that h...
Source: Pharmacology and Therapeutics - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 25 May 2018Source: Biochimica et Biophysica Acta (BBA) - Reviews on CancerAuthor(s): Yaqin Shi, Fang Yang, Doudou Huang, Xiaoxiang GuanAbstractAndrogen receptor (AR) targeted treatment has shown promising preliminary results in triple negative breast cancer (TNBC). Identification of AR-associated signaling pathways is of great significance for in-depth understanding of their roles in pathogenesis of TNBC. To meet this objective, preclinical and clinical studies were conducted to clarify the biological interactions of AR signaling and combination strategies based on AR-targeted therapy. Bi...
Source: Biochimica et Biophysica Acta (BBA) Reviews on Cancer - Category: Cancer & Oncology Source Type: research
Publication date: Available online 5 April 2018Source: Acta Pharmaceutica Sinica BAuthor(s): Zijun Zhao, Yu Chen, Ngiambudulu M. Francisco, Yuanqing Zhang, Minhao WuAbstractChimeric antigen receptor T cell (CAR-T cell) therapy is a novel adoptive immunotherapy where T lymphocytes are engineered with synthetic receptors known as chimeric antigen receptors (CAR). The CAR-T cell is an effector T cell that recognizes and eliminates specific cancer cells, independent of major histocompatibility complex molecules. The whole procedure of CAR-T cell production is not well understood. The CAR-T cell has been used predominantly in t...
Source: Acta Pharmaceutica Sinica B - Category: Cancer & Oncology Source Type: research
National Cancer Institute (NCI) researchers recently reported complete and durable regression of chemorefractory metastaticERBB2-negative and ER-positive breast cancer in a woman who received an experimental immunotherapy. Thecase report, published recently inNature Medicine, involved a 49-year-old patient whose late-stage cancer was progressing despite multiple lines of chemotherapy and hormone treatments.
Source: JAMA - Category: General Medicine Source Type: research
Publication date: Available online 19 June 2018Source: Pharmacology &TherapeuticsAuthor(s): Filipa Lynce, Ayesha N. Shajahan-Haq, Sandra M. SwainAbstractDysregulation of the cyclin dependent kinase pathway in luminal breast cancer creates a new therapeutic opportunity for estrogen receptor positive breast cancer. Initial pan-CDK inhibitors were associated with extensive toxicities but in recent years, the development of potent specific CDK inhibitors with favorable tolerability has driven renewed interests in this class of targeted therapies. Palbociclib, ribociclib and abemaciclib are specific CDK4/6 inhibitors that h...
Source: Pharmacology and Therapeutics - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 2 November 2017Source: Seminars in Cancer BiologyAuthor(s): D. Hammerl, M. Smid, A.M. Timmermans, S. Sleijfer, J.W.M. Martens, R. DebetsAbstractThere is an increasing awareness of the importance of tumor – immune cell interactions to the evolution and therapy responses of breast cancer (BC). Not surprisingly, numerous studies are currently assessing the clinical value of immune modulation for BC patients. However, till now durable clinical responses are only rarely observed. It is important to realize that BC is a heterogeneous disease comprising several histological and molecular s...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 25 May 2018Source: Biochimica et Biophysica Acta (BBA) - Reviews on CancerAuthor(s): Yaqin Shi, Fang Yang, Doudou Huang, Xiaoxiang GuanAbstractAndrogen receptor (AR) targeted treatment has shown promising preliminary results in triple negative breast cancer (TNBC). Identification of AR-associated signaling pathways is of great significance for in-depth understanding of their roles in pathogenesis of TNBC. To meet this objective, preclinical and clinical studies were conducted to clarify the biological interactions of AR signaling and combination strategies based on AR-targeted therapy. Bi...
Source: Biochimica et Biophysica Acta (BBA) Reviews on Cancer - Category: Cancer & Oncology Source Type: research
Publication date: Available online 5 April 2018Source: Acta Pharmaceutica Sinica BAuthor(s): Zijun Zhao, Yu Chen, Ngiambudulu M. Francisco, Yuanqing Zhang, Minhao WuAbstractChimeric antigen receptor T cell (CAR-T cell) therapy is a novel adoptive immunotherapy where T lymphocytes are engineered with synthetic receptors known as chimeric antigen receptors (CAR). The CAR-T cell is an effector T cell that recognizes and eliminates specific cancer cells, independent of major histocompatibility complex molecules. The whole procedure of CAR-T cell production is not well understood. The CAR-T cell has been used predominantly in t...
Source: Acta Pharmaceutica Sinica B - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Funding | Immunotherapy | Learning | Research | Science | Universities & Medical Training